Evidence map›Paper›PMID 25393531›Full record

ArticlePloS one2014

Structure-activity relationships of novel salicylaldehyde isonicotinoyl hydrazone (SIH) analogs: iron chelation, anti-oxidant and cytotoxic properties.

Eliška Potůčková, Kateřina Hrušková, Jan Bureš, Petra Kovaříková, Iva A Špirková, Kateřina Pravdíková, Lucie Kolbabová, Tereza Hergeselová, Pavlína Hašková, Hana Jansová and 8 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 2 countries.

Eliška PotůčkováCharles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
Kateřina HruškováCharles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
Jan BurešCharles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
Petra KovaříkováCharles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
Iva A ŠpirkováCharles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
Kateřina PravdíkováCharles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
Lucie KolbabováCharles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
Tereza HergeselováCharles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
Pavlína HaškováCharles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
Hana JansováCharles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
Miloslav MacháčekCharles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
Anna JirkovskáCharles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
Vera RichardsonMolecular Pharmacology and Pathology Program, Bosch Institute and Department of Pathology, University of Sydney, Sydney, Australia.
Darius J R LaneMolecular Pharmacology and Pathology Program, Bosch Institute and Department of Pathology, University of Sydney, Sydney, Australia.
Danuta S KalinowskiMolecular Pharmacology and Pathology Program, Bosch Institute and Department of Pathology, University of Sydney, Sydney, Australia.
Des R RichardsonMolecular Pharmacology and Pathology Program, Bosch Institute and Department of Pathology, University of Sydney, Sydney, Australia.
Kateřina VávrováCharles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
Tomáš ŠimůnekCharles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
Charles University · CZUniversity of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Salicylaldehyde isonicotinoyl hydrazone (SIH) is a lipophilic, tridentate iron chelator with marked anti-oxidant and modest cytotoxic activity against neoplastic cells. However, it has poor stability in an aqueous environment due to the rapid hydrolysis of its hydrazone bond. In this study, we synthesized a series of new SIH analogs (based on previously described aromatic ketones with improved hydrolytic stability). Their structure-activity relationships were assessed with respect to their stability in plasma, iron chelation efficacy, redox effects and cytotoxic activity against MCF-7 breast adenocarcinoma cells. Furthermore, studies assessed the cytotoxicity of these chelators and their ability to afford protection against hydrogen peroxide-induced oxidative injury in H9c2 cardiomyoblasts. The ligands with a reduced hydrazone bond, or the presence of bulky alkyl substituents near the hydrazone bond, showed severely limited biological activity. The introduction of a bromine substituent increased ligand-induced cytotoxicity to both cancer cells and H9c2 cardiomyoblasts. A similar effect was observed when the phenolic ring was exchanged with pyridine (i.e., changing the ligating site from O, N, O to N, N, O), which led to pro-oxidative effects. In contrast, compounds with long, flexible alkyl chains adjacent to the hydrazone bond exhibited specific cytotoxic effects against MCF-7 breast adenocarcinoma cells and low toxicity against H9c2 cardiomyoblasts. Hence, this study highlights important structure-activity relationships and provides insight into the further development of aroylhydrazone iron chelators with more potent and selective anti-neoplastic effects.

Indexed as

AldehydesAntineoplastic AgentsAntioxidantsCell LineHumansHydrazonesHydrogen PeroxideIron Chelating AgentsMCF-7 CellsMyoblastsOxidative StressStructure-Activity RelationshipAldehydesAntineoplastic AgentsAntioxidantsHydrazonesHydrogen PeroxideIron Chelating Agentssalicylaldehyde isonicotinoyl hydrazone

Identifiers

PMID25393531
PMCPMC4231169
OpenAlexW2070793137

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.